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Abstract We have previously reported that protease-activated receptor 1 (PAR1 or thrombin receptor) is over-
expressed in metastatic prostate cancer cell lines compared to prostate epithelial cells. In this study, we examined 1,074
prostate biopsies by tissue microarray analysis and demonstrated that PAR1 expression is significantly increased in
prostate cancer compared to normal prostate epithelial cells and benign prostatic hyperplasia. We hypothesized that
PAR1activation contributed toprostate cancer cell progression.Wedemonstrated that stimulationof PAR1by thrombinor
thrombin receptor activating peptide (TRAP6), in androgen-independent DU145 and PC-3 cells resulted in increased
DNA binding activity of the NFkB p65 subunit. IL-6 and IL-8 levels were also elevated in conditioned media by at least
two-fold within 4–6 h of PAR1 activation. This induction of cytokine production was abrogated by pretreatment of cells
with the NFkB inhibitor caffeic acid phorbol ester. The p38 and ERK1/2 MAPK signaling cascades were also activated by
PAR1 stimulation, whereas the SAPK/JNK pathway was unaffected. Inhibition of p38 and ERK1/2 by SB-203589 and PD-
098059, respectively, did not abrogateNFkB activity, suggesting an independent induction ofNFkBby PAR1 stimulation.
Furthermore, TUNEL assay showed that activation of PAR1 attenuated docetaxel induced apoptosis through the
upregulation of the Bcl-2 family protein Bcl-xL. Akt activation was not observed, suggesting that drug resistance induced
by PAR1was independent of PI3K signaling pathway. Because thrombin and PAR1 are over-expressed in prostate cancer
patients, targeting the inhibitionof their interactionmayattenuateNFkB signaling transduction resulting in decreaseddrug
resistance and subsequent survival of prostate cancer cells. J. Cell. Biochem. 96: 641–652, 2005.  2005 Wiley-Liss, Inc.
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The multifunctional serine protease throm-
bin is a key activator of the coagulation cascade
and we have previously reported that protease-
activated receptor 1 (PAR1 or thrombin recep-
tor) is over-expressed in metastatic prostate
cancer cell lines compared to prostate epithelial
cells. In addition to being responsible for plate-
let aggregation and converting fibrinogen to
fibrin, thrombin also induces cellular responses
such as proliferation and release of angiogenic
factors [Zain et al., 2000; Huang et al., 2001;
Maragoudakis et al., 2002]. Many patients with
advanced cancer, including prostate cancer,
suffer from thromboses due to excessive activa-
tion of the coagulation system [Kohli et al.,
2002]. In many experimental systems, stimula-
tion of cancer cells with thrombin is associated
with modulation of cell adhesion, invasive-
ness, and metastasis [Nierodzik et al., 1992;
Wojtukiewicz et al., 1993; Walz and Fenton,
1994].
Thrombin elicits cellular responses through
the activation of a family of G protein-coupled
protease-activated receptors (PARs) [Coughlin,
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1999]. Four knownmembers of the PARs family
have been identified: PAR1 and PAR3 are
activated by thrombin, PAR2 is activated by
trypsin, and PAR4 can be activated by both
trypsin and thrombin [Vu et al., 1991]. The
expression of PAR1 has been associated with
tumor growth and increased metastasis [Even-
Ram et al., 2001; Yin et al., 2003]. Cleavage in
the extended amino terminus of PAR1 by thro-
mbin unmasks a new tethered ligand, which
serves as an intramolecular activator. Thus,
activation of PAR1 by thrombin is irreversible
and can only be terminated by intracellular
receptor recycling and degradation [Coughlin,
1999]. Identified signaling pathways that are
activated by thrombin-mediated PAR1 activa-
tion include the phosphatidylinositol 3-kinase
(PI3K) [Chalmers et al., 2003], protein kinase C
[Lidington et al., 2000], c-Jun N-terminal
kinase (JNK) [Mitsui et al., 1998], p38 MAPK
[Marin et al., 2001], RhoGTPase [Ming et al.,
2004], and nuclear factor NFkB [Rahman et al.,
2002].
Previous reports have shown that the tran-
scription factor NFkB is constitutively active
in androgen-insensitive prostate cancer cells
[Palayoor et al., 1999; Suh et al., 2002; Zerbini
et al., 2003]. Furthermore, tumor samples with
high Gleason grades also have high nuclear
expression of RelA (p65) [Suh et al., 2002].
NFkB/Rel proteins regulate the expression of
genes involved in cell growth and differentia-
tion, inflammatory responses, and apoptosis.
The NFkB/Rel proteins belong to two different
classes distinguishable by their mode of synth-
esis and transactivationproperties [Karin et al.,
2002]. RelA (p65), RelB, and c-Rel are synthe-
sized in their mature form, while p50/p105
(NFkB1) and p52/p105 (NFkB2) require proteo-
lytic processing toproducematureDNAbinding
proteins. These proteins form various homo-
and hetero-dimers that exist in the inactive
forms in the cytoplasm in complex with the
inhibitory protein subunit IkB. When IkB
becomes phosphorylated by the IkB kinase
(IkK), it is marked for ubiquination and protea-
somal degradation. Disassociation from IkB
allows NFkB to translocate to the nucleus.
Subsequent phosphorylation facilitates binding
to a specific DNA sequence, resulting in gene
transcription.
Due to the fact that excessive amounts of
thrombin are generated in prostate cancer
patients and we and others have previously
reported that PAR1 is upregulated in prostate
cancer cell lines [Chay et al., 2002; Liu et al.,
2003], we hypothesized that activation of PAR1
contributed to prostate cancer progression. We
compared PAR1 expression in normal and
cancerous prostate tissues and elucidated the
function of PAR1 in prostate cancer by examin-
ing the effects of PAR1 activation on signaling
pathways including NFkB DNA binding activ-
ity, IkB phosphorylation, and MAPK signaling
pathways. We also investigated the effects of




Immunohistochemistry of PAR1 expression
was performed on prostate tissue microarrays
(TMAs) as previously described [Rubin et al.,
2002]. Standard biotin–avidin complex techni-
que and a monoclonal antibody against PAR1
(Immunotech, Marseille, France) was used to
evaluate PAR1 expression. Slides were counter-
stained with hematoxylin. Protein expression was
scored as negative (score¼ 1), weak (score¼ 2),
moderate (score¼ 3), or strong (score¼ 4) using
a system that has been validated previously
[Dhanasekaran et al., 2001]. Expression was
graphically represented using error bars with
95% confidence intervals. Differences between
types of tissues were evaluated using ANOVA
with a post hoc Scheffe analysis to takemultiple
tissue types into account.
Cell Culture
Human prostate cancer cell lines PC-3 and
DU145 were obtained from ATCC (Manassas,
VA). They were maintained in RPMI 1640
supplemented with 10% fetal bovine serum
and 100U/ml penicllin, 100 mg/ml streptomycin,
and 250 ng/ml amphotericin B (all from In-
vitrogen, Carlsbad, CA) at 378C in a 5% CO2
humidified incubator. Stock solution of 1 mM
thrombin (Sigma, St. Louis, MO) and 6 mM
thrombin receptor activating peptide SFLLRN
(TRAP6) (Bachem, King of Prussia, PA) were
prepared in sterile distilled water and stored at
208C.
Cytosolic and Nuclear Protein Extraction
Cells were collected in ice-cold PBS and
pelleted by centrifugation at 400g for 5 min.
Cells were lysed with ice-cold hypotonic lysis
642 Tantivejkul et al.
buffer (10 mM HEPES, pH 7.9; 1.5 mM MgCl2,
10 mM KCl, 0.5 mM DTT, and 0.1% Triton
X-100) containing 1 mg/ml each of aprotinin,
leupeptin and pepstatin A, 1 mM PMSF, 1 mM
NaF, and 1 mMNa3VO4. Cells were pelleted by
centrifugation at 8,000g for 10 min and super-
natant (cytosolic fraction) was snap-frozen
immediately. The remaining cell pellet was in-
cubated for 30 min on ice in nuclear extraction
buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2,
420 mMNaCl, 0.2 mMEDTA, 0.5 mMDTT, 1%
Nonadet P-40, and 25% v/v glycerol) containing
1 mg/ml each of aprotinin, leupeptin and pep-
statin A, 1 mM PMSF, 1 mM NaF, and 1 mM
Na3VO4.Nuclear suspensionwas centrifugedat
16,000g for 5min and nuclear extract was snap-
frozen immediately.Protein concentrationswere
determined by Biorad protein determination
reagent (Biorad, Hercules, CA).
NFkB Transcription Factor Assay
The NFkB transcription factor assay kits
(Chemicon International, Temecula, CA) were
used to quantitate nuclear activation of unsti-
mulated and PAR1-stimulated cells. Nuclear
extracts were incubated with NFkB capture
probe for 1 h at room temperature. Contents
were then transferred to an ELISA plate and
incubated for 1 h more at room temperature.
Plates were washed and each well was incu-
bated with anti-NFkB p65 or anti-NFkB p50
antibodies followed by anti-rabbit IgG-HRP
conjugated secondary antibody. Bound NFkB
components were detected by chemiluminescent
detection reagent and absorbance was mea-
sured with a microplate luminometer (Molec-
ular Devices, Sunnyvale, CA).
Cytokine ELISA Assays
Cells at 60%–80% confluency were plated in
6-well plates and starved for 2 h prior to
treatment with thrombin or TRAP6 in serum-
free RPMI 1640 supplemented with 1% penicil-
lin and streptomycin. Conditioned medium
from each well was collected at various time
points and stored at 208C until use. IL-6
expression in cell culture supernatants was
determined by using ChemiKineTM human IL-6
sandwich ELISA kit (Chemicon International,
Temecula, CA) and IL-8 expression was deter-
mined by using Quantikine human IL-8 immu-
noassay kit (R&D Systems, Minneapolis, MN)
according to the protocols supplied by the
manufacturers.
TUNEL Staining
Cells were seeded in chamber slides to 60%–
80% confluency. They were starved for 2 h and
stimulated with either thrombin or TRAP6 in
serum-free RPMI 1640 supplemented with 1%
penicillin and streptomycin for 4 h prior to
addition of 100 nM taxotere overnight. Cells
were then fixed in freshly prepared 4% paraf-
olmaldehyde in PBS, pH 7.4. After blocking
with 3% H2O2 in methanol, cells were permea-
bilized with 0.1% Triton X-100 in 0.1% sodium
citrate. They were then labeled with TUNEL
reaction mixture (Roche, Indianapolis, IN) for
1 h at 378C in a humidified atmosphere in the
dark. DAPI was used to visualize the nucleus.
Samples were analyzed under a fluorescence
microscope at 450 nm excitation and 565 nm
emission.
Western Blot and Immunoblotting
Cells were lysed in RIPA buffer (50 mM Tris-
HCl, pH 7.4, 1% NP-40, 150 mM NaCl, 1 mM
EDTA, 1mMPMSF, 1mMNa3VO4, 1mMNaF,
1mMokadaic acid, and1mg/ml eachof aprotinin,
leupeptin, and pepstatin). Proteins were sepa-
rated in 10%–15% SDS–PAGE gels and trans-
ferred onto PVDFmembrane. Membranes were
blocked with 5% milk in PBST (0.1% Tween in
PBS) for 1 h at room temperature. They were
incubated overnight at 48C with primary anti-
bodies: anti-phospho p38 (Thr180/Tyr182),
anti-phospho ERK1/2 (Thr202/Tyr204), anti-
phospho SAPK/JNK (Thr183/Tyr185), anti-
phospho ATF-2, anti-phospho Akt (Ser473),
anti-Akt, anti-phospho GSK3a/b (Ser21/9),
anti-GSK3b, anti-phospho IkB, anti-IkB, anti-
NFkB, anti-Bcl-xL, anti-Bcl2, anti-survivin,
anti-Bad, anti-Mcl-1, and anti-actin (all from
Cell Signaling Technology, Beverly, MA).
Membranes were washed three times prior to
incubation with secondary antibodies (HRP-
conjugated anti-rabbit from Cell Signaling
Technology or HRP-conjugated anti-mouse
from Santa Cruz Biotechnology, Santa Cruz,
CA) for 1 h at room temperature. Bands were
visualized by ECL chemiluminescent (Pro-
mega, Madison, WI) and quantitated using
Image J software (NCI, Bethesda, MD).
Statistical Analysis
Results obtained from each experiment are
expressed as mean standard deviation of
triplicates. To perform statistical analysis, the
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two-tailed Student’s t-test was used; a p value
less than 0.05 is considered significant.
RESULTS
PAR1 Is Overexpressed in Prostate Cancer
Over-expression of PAR1 has been previously
reported in human prostate cancer cell lines
[Chay et al., 2002; Liu et al., 2003]. Tissue
microarray of 1,074 samples collected from
normal prostate, benign prostatic hyperplasia
(BPH), prostatic intraepithelial neoplasia (PIN),
cancerous prostates, and metastatic lesions
revealed that PAR1 expression increased pro-
portionately to the degree of prostate disease
(Fig. 1). BPH expressed higher levels of PAR1
than normal prostate stroma (BPH 1.4 0.1,
stroma 1.1 0.2 stain intensity). Tissues from
high grade PIN and prostate adenocarcinoma
exhibited significantly higher magnitude of
PAR1 expression compared to normal prostate
stroma, BPH, and atrophic prostate tissues
(PIN 2.7 0.2, prostate cancer 2.5 0.1 stain
intensity, respectively), suggesting that up-
regulation of PAR1 is an early event in prostate
tumorigenesis.
Stimulation of PAR1 Activates
NFkB Signal Transduction
To elucidate the significance of PAR1 signal-
ing in prostate cancer cells, we performed
transcription factor activation assay using
nuclear protein extracts to evaluate NFkB
DNA binding activity. We used two androgen-
insensitive cell lines which have high (PC-3
cells) and low levels (DU145 cells) of PAR1
expression [Chay et al., 2002]. Cells were stimu-
lated with 2 and 10 nM thrombin (physiological
Fig. 1. PAR1 expression increases in prostate cancer. An
analysis of 1,074 samples showed a significant increase in
PAR1 expression in high grade PIN and prostate cancer
compared to normal prostate stroma, benign prostate hypertro-
phy, and atrophic prostate tissue. Representative TMA images of
normal prostate, high grade PIN, and prostate adenocarcinoma
stained with PAR1 monoclonal antibody and counterstained
with hematoxylin are shown. Slides were scored as described in
‘‘Materials and Methods.’’ The graph represents scored PAR1
expression 95% confidence intervals.
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and pharmacological concentration, respec-
tively), and 20 and 100 mM TRAP6, a PAR1-
specific activator, for 30min. The result demon-
strated no change in NFkB p50 subunit DNA
binding activity in both DU145 and PC-3 cells
(Fig. 2A,B). However, TRAP6 stimulation of
DU145 cells resulted in two-fold increase of
NFkB p65 subunit DNA binding activity. Dose-
dependent increase of p65 subunit in PC-3 cells
was also observed after PAR1 stimulation with
either thrombin (1.5-fold increase with 2 nM
thrombin and 1.8-fold increase with 10 nM
thrombin) or TRAP6 (two-fold increase with
20 mMTRAP6 and 3.1-fold increasewith 100 mM
TRAP6, p< 0.01). To confirm that NFkB was
activated, we also analyzed phosphorylation
status of IkB by Western blot analysis of the
cytosolic protein extracts (Fig. 2C,D). DU145
cells demonstrated a three- to five-fold increase
in IkB phosphorylation when stimulated with
thrombin or TRAP6. Treatment of PC-3 cells
with thrombin increased IkB phosphorylation
by two- to three-fold compared to untreated
control cells (p< 0.05), whereas TRAP6 induced
5.7- to 8-fold increase in IkB phosphorylation
(p< 0.01). Since IkB phosphorylation releases
NFkB for translocation into the nucleus, the
result supported our findings that stimulation
of PAR1 increased NFkB DNA binding activity
in prostate cancer cells.
To evaluate the extent of NFkB activity indu-
ced through PAR1, we examined the production
Fig. 2. Stimulation of PAR1 specifically activates NFkB p65
subunit transcription factor activation in prostate cancer.
Transcription factor assays were used to assess DNA binding
activity of the p50 (gray bars) or p65 (white bars) subunits in the
nuclear extracts of DU145 and PC-3 cells stimulated with
thrombin (Thr) or TRAP6 for 30 min (A, B, *, p<0.05). Each
experiment was performed in triplicate and the result expressed
as mean standard deviation. Cytosolic extracts (15 mg) were
separated on 10% SDS gels and immunoblotted for IkB
phosphorylation (C, D). The membranes were stripped and
reprobed for total IkB expression and the ratio of IkB
phosphorylation to total IkB expression was obtained by
analyzing signal intensity of autoradiographic bands. Changes
in IkB phosphorylation were quantitated as fold change
compared to untreated control. Each experiment was performed
in duplicate and the result expressed as mean standard
deviation.
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of IL-6 and IL-8 cytokines by ELISA. Condi-
tioned media collected over a 24 h-period from
cells that have been treated with or without
thrombin or TRAP6 was used to quantify IL-6
and IL-8 levels. Our result showed that DU145
constitutively produced less IL-6 and IL-8 than
PC-3 cells. Conditioned media of DU145 cells
collected after 24 h of incubation contained
41.7 1.5 pg/ml IL-6 and 258.6 21.1 pg/ml
IL-8 compared to 230.4 67.5 pg/ml IL-6 and
24675 3914 pg/ml IL-8 produced by PC-3 cells
(Fig. 3). However, within 4–6 h of stimulation
with thrombin or TRAP6, IL-6 and IL-8 levels
increased by at least two to six-fold in DU145
cells (Fig. 3A,C). This increase in cytokine
production was maintained over the 24 h-
period. Similarly, thrombin and TRAP6 also
induced PC-3 cells to increase IL-8 production
by as much as eight-fold within 8 h (Fig. 3B,D).
Furthermore, cytokine production induced by
PAR1 stimulation was abrogated when cells
were pretreated with CAPE (50 mg/ml), an inhi-
bitor of NFkB activity, suggesting that cytokine
production was dependent on NFkB activation
(Fig. 4).
MAPKs Are Activated by PAR1 Stimulation
NFkB signal transduction in prostate cancer
has been shown to be regulated by the MAPK
signaling pathway [Je et al., 2004]. Here we
investigated PAR1-mediated phosphorylation
and activation of p38, ERK1/2, and SAPK/JNK
MAP kinase signaling cascades byWestern blot
analysis. DU145 and PC-3 cells stimulatedwith
thrombin or TRAP6 for 30 min resulted in a
significant increase in p38 and ERK1/2 phos-
phorylation compared to untreated control cells
(Fig. 5). SAPK/JNK phosphorylation remained
unaffected in both DU145 and PC-3 cells by
PAR1 stimulation. Furthermore, phosphoryla-
tion of pMAPKAPK2, a downstream mediator
of p38 and ERK1/2 signaling, was induced by
30 min stimulation with 10 nM thrombin and
100 mM TRAP6. Additionally, phosphorylation
of HSP27 and ATF-2 was induced by PAR1
stimulation in both DU145 and PC-3 cells.
It has been reported that inhibition of p38
by MAPK inhibitor in endothelial cells reduced
ATF-2 activity, thereby suppressing NFkB
nuclear translocation [Kaur et al., 2003]. To
determine whether PAR1-induced NFkB acti-
vation was dependent on MAPK activity, we
treated DU145 and PC-3 cells with TRAP6
(100 mMfor 30min) in the presence and absence
of a p38 (SB-203589) or ERK1/2 (PD-098059)
inhibitor. Neither inhibitor suppressed TRAP6-
induced p65 subunit DNA binding activity in
DU145 or PC-3 cells, suggesting that NFkB
activation through PAR1 is independent of the
p38 and ERK1/2 activities (Fig. 6).
Fig. 3. PAR1 activation stimulates cytokine productions in prostate cancer cells. The amount of IL-6 (A, B)
and IL-8 (C,D) producedbyDU145andPC-3 cells (5 105 cells perwell) treatedor untreatedwith thrombin
(Thr) or TRAP6 was measured by ELISA as described in ‘‘Materials and Methods.’’ Conditioned media was
collected at the indicated time points and kept frozen at 208C until the assay was performed. Each data
point represents the mean standard deviation of three separate samples.
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Suppression of Docetaxel-Induced Apoptosis
To investigate the functional significance of
PAR1 activation, we used docetaxel to induce
apoptosis. DU145 cells were pretreated with 10
nM thrombin or 100 mM TRAP6 for 4 h prior to
the addition of 100 nM docetaxel overnight.
Apoptotic cells were identified by TUNEL
staining of the nucleus (Fig. 7). Untreated
control, thrombin-treated or TRAP6-treated
cells did not have cells undergoing apoptosis.
Docetaxel induced apoptosis in approximately
20% of cells as evident by positive TUNEL
staining. However, pretreatment of prostate
cancer cells with either thrombin or TRAP6
suppressed docetaxel-induced apoptosis. Simi-
lar results were observed in PC-3 cells (data not
shown).
To determine the mechanism by which PAR1
stimulation inhibited apoptosis, we examined
the expression levels of Bcl-2 family member
proteins by Western blot. Cells were treated
with thrombin or TRAP6 for 4 h and total cell
lysates were collected for analysis (Fig. 8). In
both cell lines, treatment with thrombin or
TRAP6 induced the upregulation of Bcl-xL
expression. Mcl-1, which is constitutively ex-
pressed in DU145 but not PC-3 cells was also
upregulated by PAR1 stimulation in DU145
cells. No significant change was detected in the
expressions of Bcl-2, Bad, and survivin in either
DU145 or PC-3 cells. To investigate whether
PI3K was involved in PAR1-induced survival,
we examined the phosphorylation state of Akt
and Gsk3a/b. No difference in the phosphory-
lation of Akt or Gsk3 a/b was observed when
cells were treated with thrombin or TRAP6 for
30 min, suggesting that PI3K is not involved.
DISCUSSION
There is no curative treatment for metastatic
prostate cancer. We have previously reported
that PAR1 is over-expressed in metastatic
prostate cancer cell lines compared to normal
prostate epithelial cells [Chay et al., 2002]. We
hypothesized that PAR1 over-expression could
contribute to prostate cancer cell progression
and survival. In this study, we examined tissue
expression of PAR1 from over 1,000 tissue sam-
ples collected fromprostate biopsies.Wedemon-
strated that PAR1 over-expression is evident
early in tumorigenesis. Previous studies have
also shown that men with advanced prostate
cancer tend to have elevated thrombin levels
[Lind et al., 2003]. Due to the fact that thrombin
and its receptor, PAR1, are present in high
levels in prostate cancer patients, we investi-
gated the role of PAR1 stimulation by thrombin
or TRAP6, a PAR1-specific activator. We report
here that PAR1 activation leads to NFkB signal
transduction which resulted in increased cell
resistance to docetaxel-induced apoptosis, via a
Bcl-xL dependent mechanism.
NFkB is known to play an important role in
the control of cell growth, differentiation,
survival, and cytokine productions. It has been
shown that activation of NFkB through stimuli
such as TGFb2 or lysophosphatitidic acid
promotes prostate cancer cell survival [Lu
et al., 2004; Raj et al., 2004]. We used two
androgen-insensitive cell lines that differ in the
levels of PAR1 expression: PC-3 cells which
have high PAR1 expression compared toDU145
Fig. 4. Inhibition of NFkB abrogates PAR1-induced cytokine
secretion. DU145 (A) and PC-3 (B) cells were pretreated with
50 mg/ml caffeic acid phorbol ester (CAPE), a specific NFkB
inhibitor, for 1h followedby theadditionof 10nM thrombin (Thr)
or 100 mM TRAP6. After 8 h of incubation, conditioned media
was collected and the amount of IL-8 produced in culture of was
measured. Each data point represents the mean standard
deviation of three separate samples.
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cells which have low PAR1 expression. We
showed that stimulation of both prostate cancer
cell lines by thrombin or TRAP6 increased
NFkB p65 subunit activation. In a study of
benign and malignant human prostate tissues,
Shukla et al. [2004] reported that NFkB p65
subunit, but not the p50 subunit, is constitu-
tively activated in human prostate cancer.
Although constitutive activation of the NFkB
p50 subunit has been shown to be critical in
mouse skin carcinogenesis model [Budunova
et al., 1999], it is less abundant and has a lower
transcriptional activity than the NFkB p65
subunit [Karin et al., 2002]. We did not see a
significant change in p50 subunit activity with
thrombin or TRAP6 stimulation, possibly due to
the low levels present in these cells.
Constitutive expression of IL-6 in androgen-
independent prostate cancer cell lines has been
reported [Zerbini et al., 2003]. Our results
demonstrated that DU145 cells produced sig-
nificantly lower amounts of IL-6 and IL-8 than
PC-3 cells under serum-depleted conditions.
However, upon stimulation with thrombin or
TRAP6, prostate cancer cells increased IL-6
and IL-8 productions by at least two-fold over
untreated control cells within 4–6 h. The
induction of IL-6 and IL-8 through PAR1 may
play a key role in prostate cancer progression.
Fig. 5. Activationof PAR1 leads to activationof p38andErk1/2MAPKsignalingpathways. Total cell lysates
(40 mg/lane) were separated by 12.5–15% SDS–PAGE and proteins were analyzed by chemiluminescence.
Fig. 6. MAPK inhibitors do not suppress NFkB activation by
TRAP6 in prostate cancer cells. Cells were pretreated with p38
inhibitor (SB-203589) and Erk1/2 inhibitor (PD-098059) for
30min prior to stimulationwith 100 mMTRAP6 for an additional
30 min. Nuclear fraction was collected from DU145 (gray bars)
and PC-3 (white bars) cells (A). NFkB p65 subunit transcription
factor activation was measured as previously described. Cyto-
solic protein extracts (15 mg/lane) were analyzed for IkB phos-
phorylation status (B). Each experiment was performed in
duplicate and the result expressed asmean standard deviation.
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Evidence suggests that IL-6 acts as a survival
factor in tumors such as multiple myeloma
[Hardin et al., 1994], esophageal carcinoma
[Leu et al., 2003], and colon cancer [Yuan et al.,
2004]. In prostate cancer, introduction of exo-
genous IL-6 conferred resistance to cytotoxic
agent-induced apoptosis [Pu et al., 2004].
Furthermore, IL-8hasbeen shown to contribute
to the development of benign prostate hyper-
plasia by stimulating growth of both benign
prostate epithelial cells and stromal cells
[Castro et al., 2004]. Orthotopic implantation
of a PC-3 cell clone that highly produces IL-8
into nude mice resulted in highly tumorigenic
and vascularized prostate tumor compared to
low IL-8 producing clone [Kim et al., 2001]. We
demonstrated that these cytokines are under
the control of NFkB and can be regulated by
PAR1 activation. Suppression of NFkB activity
by its inhibitor CAPE suppressed IL-6 (data not
shown) and IL-8 productions in prostate cancer
cells, suggesting an important mechanism of
NFkB-mediated survival.
NFkB signal transduction in prostate cancer
has been shown to be regulated by the p38
MAPKsignalingpathway [Shimada et al., 2003;
Je et al., 2004]. In platelets, activation of p38 by
thrombin leads to NFkB-dependent leukocyte
recruitment [Kaur et al., 2003]. In macro-
phages, all three MAPK signaling pathways
were activated by thrombin [Kang et al., 2003].
However, our results indicated that NFkB
activation via PAR1 is independent of the
MAPK signaling pathways. Nonetheless, PAR1
activation resulted in the activation of p38 and
ERK1/2 signaling cascades, whereas the SAPK/
Fig. 7. TUNEL assay showed that thrombin or TRAP6 suppressed docetaxel-induced apoptosis. DU145
cells were pretreated with thrombin or TRAP6 for 4 h followed by induction of apoptosis with 100 nM
docetaxel. After incubation overnight, the slides were fixed and labeled with TUNEL labeling reagent (right
panel) and DAPI (left panel) for nuclear morphology. The experiment was repeated three times.
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JNKpathwaywas unaffected. It is possible that
p38, ERK1/2, and NFkB are all required for the
survival of prostate cancer cells and that PAR1-
dependent NFkB activation is regulated by
alternative mechanisms.
Activation of the PI3K signaling cascade has
long been considered a crucial pathway of cell
survival, and the loss of the tumor suppressor
gene PTEN function and expression in prostate
cancer has been well-characterized [Deocampo
et al., 2003; Koksal et al., 2004]. The loss of
PTEN, anegative regulator of PI3K, leads to the
dysregulation of PI3K/Akt signaling cascade,
which promotes cell survival in many types of
cancer. However, our results suggest that
PAR1-induced cell survival is independent of
Akt activation, but occurs through the upregu-
lation of Bcl-xL. Although bothBcl-2 andBcl-xL
prevent the release of cytochrome c from the
mitochondria, therebyblockingapoptosis, recent
studies have indicated that Bcl-xL may play a
more crucial role in prostate cancer cell anti-
apoptosis mechanism than Bcl-2. Suppression
of Bcl-xL by oligonucleotides, but not Bcl-2,
rendered cells more sensitive to induction of
apoptosis [Lebedeva et al., 2000]. It has also
been reported that over-expression of Bcl-xL
by transfection protected prostate cancer cells
from the PI3K-specific inhibitor LY294002-
induced apoptosis [Yang et al., 2003]. Likewise,
prostate cancer cells that have been exposed to
exogenous IL-6 become resistant to chemother-
apy due to the overexpression of Bcl-xL and not
Bcl-2 [Pu et al., 2004]. Thus, Bcl-xL expression
maybe the crucial protein inpromotingprostate
cancer cell survival in the absence of PI3K/Akt
signaling pathway.
In this study,we have shown that stimulation
of PAR1, which is over-expressed in prostate
cancer, plays an important role in prostate can-
cer cell survival through the activation of the
NFkB signaling pathway (Fig. 9). This resulted
in the increase production of IL-6 and IL-8 in
prostate cancer cells, which have been impli-
cated in the development of drug resistance and
Fig. 8. PAR1 stimulation protects prostate cancer cells from
apoptosis through the Bcl-2 family proteins, but not Akt. Cells
were serum-starved for 2 h followed by stimulation with 10 nM
thrombin or 100 mM TRAP6 for 4 h. Proteins from cell lysates
(40 mg/lane) were collected and separated on 12.5–15% SDS
gels and probed for Bcl-xL, Bcl-2, Bad,Mcl-1, survivin, and actin
(A). Anti-phospho Akt and anti-phospho Gsk3a/b were used to
detect Akt and Gsk3a/b activation status (B). Membranes were
then stripped and rehybridized to detect total expression of Akt
and Gsk3a/b. Each experiment was performed in duplicate and
repeated three times.
Fig. 9. Schematic representation of PAR1-induced signal
transduction in prostate cancer. Activation of PAR1 by either
thrombinor TRAP6 resulted in increasedNFkBp65 subunitDNA
binding activity. This resulted in upregulation of cytokine
productions in prostate cancer. The p38 and ERK1/2 signaling
cascades were also activated by PAR1. These pathways may
work together to induce prostate cancer cell survival through the
expression of Bcl-xL.
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tumorigenesis. Furthermore, induction of PAR1
signaling attenuated cytotoxic drug-induced
apoptosis through the up-regulation of Bcl-xL.
Because thrombin, the ligand for PAR1 is rea-
dily available in the serum of prostate cancer
patients, its ability to activate PAR1 may
contribute to prostate cancer progression and
evasion of apoptosis. In recent years, NFkB
inhibitors have been developed extensively
since dysregulation of NFkB signal has been
implicated in many types of malignancies.
Inhibition of the PAR1-thrombin interaction
may contribute to the attenuation of NFkB
signaling pathway and, therefore, may be bene-
ficial to the management of the disease.
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